8-K current report · filed Nov 9, 2026

Aldeyra Therapeutics, Inc. (ALDX) 8-K Current Report: November 9, 2026

Item 8.01ALDX overview

Short answer

Aldeyra Therapeutics, Inc. (ALDX) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 8.01 (Other Events). FDA review-jurisdiction transfer requested from Ophthalmology to Hematologic Malignancies 2 for ADX-2191’s PVRL program.

Aldeyra Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • FDA review-jurisdiction transfer requested from Ophthalmology to Hematologic Malignancies 2 for ADX-2191’s PVRL program
  • SPA protocol withdrawn, eliminating prior FDA agreement on trial design and planned analysis
  • Planned PVRL trial on hold pending FDA decision, with clinical program expected to require redesign
  • Potentially larger, longer, costlier trial could delay NDA resubmission, approval and orphan-drug exclusivity
  • Regulatory delays could shorten cash runway, accelerate financing needs and pressure ALDX shares

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Aldeyra Therapeutics, Inc. 8-K filings

Get the next ALDX 8-K as it lands

Follow ALDX for push alerts, or ask the research agent what this filing means.